A detailed history of Royal Bank Of Canada transactions in Chimerix Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 739 shares of CMRX stock, worth $716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
739
Previous 52,400 98.59%
Holding current value
$716
Previous $55,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.87 - $1.05 $44,945 - $54,244
-51,661 Reduced 98.59%
739 $0
Q1 2024

May 15, 2024

SELL
$0.91 - $1.26 $28,993 - $40,144
-31,861 Reduced 37.81%
52,400 $55,000
Q4 2023

Feb 14, 2024

BUY
$0.9 - $1.06 $774 - $912
861 Added 1.03%
84,261 $80,000
Q3 2023

Nov 14, 2023

BUY
$0.94 - $1.23 $19,874 - $26,005
21,143 Added 33.96%
83,400 $80,000
Q2 2023

Aug 14, 2023

BUY
$1.1 - $1.54 $63,186 - $88,460
57,442 Added 1192.98%
62,257 $75,000
Q1 2023

May 15, 2023

SELL
$1.19 - $2.09 $9,286 - $16,310
-7,804 Reduced 61.84%
4,815 $6,000
Q4 2022

Feb 14, 2023

BUY
$1.67 - $2.35 $19,361 - $27,245
11,594 Added 1131.12%
12,619 $23,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $2.76 $995 - $1,517
550 Added 115.79%
1,025 $2,000
Q2 2022

Aug 15, 2022

SELL
$1.34 - $5.34 $5,374 - $21,418
-4,011 Reduced 89.41%
475 $1,000
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $48,396 - $71,855
-10,567 Reduced 70.2%
4,486 $21,000
Q4 2021

Feb 14, 2022

BUY
$5.23 - $7.18 $46,756 - $64,189
8,940 Added 146.25%
15,053 $96,000
Q3 2021

Nov 15, 2021

BUY
$5.94 - $8.75 $6,409 - $9,441
1,079 Added 21.43%
6,113 $38,000
Q2 2021

Aug 16, 2021

BUY
$7.54 - $9.79 $37,956 - $49,282
5,034 New
5,034 $40,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.